<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745719</url>
  </required_header>
  <id_info>
    <org_study_id>A111-102</org_study_id>
    <nct_id>NCT00745719</nct_id>
  </id_info>
  <brief_title>Parathyroidectomy in Endstage Renal Disease</brief_title>
  <official_title>A Pilot Study to Evaluate the Efficacy of Total Parathyroidectomy in Retarding Cardiovascular Calcification in End-stage Renal Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the hypothesis that total parathyroidectomy retards cardiovascular calcification,
      improves bone mineral density, reduces cardiac hypertrophy and arterial stiffening in
      end-stage renal disease patients on maintenance dialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary hyperparathyroidism (SHPT) in patients with end-stage renal disease contributes to
      increased cardiovascular morbidity and mortality via different mechanisms. Uncontrolled
      hyperparathyroidism is associated with left ventricular hypertrophy and has been implicated
      in the development of cardiac interstitial fibrosis and diastolic dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in vascular and valvular calcium scores</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral density</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in aortic pulse wave velocity,</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in left ventricular mass, volume and function</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in quality of life scores</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in iPTH</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Serum calcium and phosphate</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in alkaline phosphatase</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in handgrip strength</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in subjective global assessment</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in serum albumin</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in inflammatory marker</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in HOMA index</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Endstage Renal Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>surgical total parathyroidectomy with forearm autografting</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>parathyroidectomy</intervention_name>
    <description>total parathyroidectomy with forearm autografting</description>
    <arm_group_label>1</arm_group_label>
    <other_name>total parathyroidectomy with forearm autografting</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Endstage renal disease patients receiving either long-term hemodialysis or peritoneal
             dialysis treatment, with elevated intact parathyroid hormone (iPTH) levels &gt; 500pg/ml
             on two or more occasions.

          -  Patients with parathyroid nodular or diffuse hyperplasia identified by ultrasound
             imaging or radioisotope scan.

          -  Patients who provide informed consent for the study.

        Exclusion Criteria:

          -  Patients with significant background valvular heart disease

          -  Patients who are unfit for general anaesthesia

          -  Patients with acute myocardial infarction within recent two months

          -  Patients with poor general condition

          -  Patients with plans for living related kidney transplant within 1 year

          -  Patients with previous history of parathyroidectomy

          -  Patients with calciphylaxis

          -  Patients with underlying active malignancy

          -  Patients with contraindication for MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela YM Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hospital, University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital, Tung Wah Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>0000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2008</study_first_submitted>
  <study_first_submitted_qc>September 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <last_update_submitted>January 14, 2017</last_update_submitted>
  <last_update_submitted_qc>January 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Angela Yee-Moon Wang</investigator_full_name>
    <investigator_title>Honorary Associate Professor</investigator_title>
  </responsible_party>
  <keyword>parathyroidectomy</keyword>
  <keyword>cardiovascular</keyword>
  <keyword>bone</keyword>
  <keyword>endstage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

